Zhou Mei, Yang Yuze, Zhang Xiaoyan, Jiao Yijie, Guo Zhenxing
Department of Hematology/Oncology, First Hospital of Tsinghua University, School of Medicine, Tsinghua University, Beijing, 100016, PR China.
Discov Oncol. 2025 Jul 1;16(1):1202. doi: 10.1007/s12672-025-03055-4.
T lymphoblastic lymphoma/acute lymphoblastic leukemia (T-LBL/ALL) is a highly aggressive hematologic malignancy, with particularly poor outcomes for refractory/relapsed (R/R) patients. This article reports the efficacy and safety of V-CHG regimen (Venetoclax, cytarabine, homoharringtonine, G-CSF) in the treatment of three R/R T-LBL/ALL cases. One 69 years old female patient with T-ALL experienced a twice relapse and achieved morphological complete remission (CR) with one cycle of V-CHG regimen. Another 65 years old female patient with T-LBL progressed to T-ALL after continuous CR for 10 months and failed by two different salvage chemotherapy regimens. She achieved minimal residual disease (MRD) negative CR with a third-line treatment based on V-CHG regimen. The third T-ALL patient was a 26 years old male who resistant to VDCP induction regimen and achieved morphological CR with one cycle of V-CHG regimen, and obtained MRD negative CR after second cycle treatment. All the three patients were well tolerated to the V-CHG regimen. The results of this study indicate that the V-CHG regimen is effective and safe for R/R T-LBL/ALL, warranting further application in the future.
T淋巴母细胞淋巴瘤/急性淋巴细胞白血病（T-LBL/ALL）是一种侵袭性很强的血液系统恶性肿瘤，难治/复发（R/R）患者的预后尤其差。本文报告了V-CHG方案（维奈克拉、阿糖胞苷、高三尖杉酯碱、粒细胞集落刺激因子）治疗3例R/R T-LBL/ALL患者的疗效和安全性。1例69岁的T-ALL女性患者经历了两次复发，接受一个周期的V-CHG方案治疗后达到形态学完全缓解（CR）。另1例65岁的T-LBL女性患者持续CR 10个月后进展为T-ALL，两种不同的挽救化疗方案均失败。她接受基于V-CHG方案的三线治疗后达到微小残留病（MRD）阴性CR。第3例T-ALL患者是1名26岁男性，对VDCP诱导方案耐药，接受一个周期的V-CHG方案治疗后达到形态学CR，第二个周期治疗后获得MRD阴性CR。所有3例患者对V-CHG方案耐受性良好。本研究结果表明，V-CHG方案治疗R/R T-LBL/ALL有效且安全，值得未来进一步应用。
